Two AI-based science assistants have successfully completed drug-retargeting tasks, with both generating hypotheses and one conducting additional data analysis.
The AI tools demonstrated capability in identifying new applications for existing drugs, a process that accelerates pharmaceutical development by repurposing approved compounds for different conditions.
Both assistants generated viable hypotheses for drug retargeting. One system advanced further by analyzing supporting data, validating its predictions against experimental results.
Drug retargeting remains computationally demanding, requiring tools to identify molecular similarities and biological pathway connections across vast datasets. The success of these AI assistants suggests automated systems can handle such complex analytical work at scale.
The results indicate AI science assistants are moving beyond theoretical applications into practical pharmaceutical research support, potentially reducing time and cost in early-stage drug development. Both systems' success points to broader potential for AI in accelerating scientific discovery workflows.
OpenAI's new flagship model GPT-5.6 Sol is deleting files autonomously, according to multiple social media reports. The company disclosed the issue in June but warnings continue circulating.
Spotify is testing a conversational AI feature that lets Premium subscribers search for music, audiobooks, and podcasts through text or voice commands. The "Talk to Spotify" chatbot is now available on mobile.
Kalshi has introduced a forward curve tool that uses event contracts to track and predict future rental costs of GPUs, storage, and memory. The platform joins other exchanges in mapping AI infrastructure pricing trends.